PamelaMunsterMD

Professor, Department of Medicine (Hematology/Oncology), UCSF; Director, Early Phase Clinical Trials Unit and Leader, Developmental Therapeutics Program, UCSF Helen Diller Family Comprehensive Cancer Center

Join to view full profile

Dr. Munster is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Munster's full profile

Already have an account?

Office
1825 4th St
San Francisco, CA 94143
Phone+1 415-885-3631

Fax+1 415-353-7021

Education & Training

Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 1996 - 1999
Indiana University School of MedicineResidency, Internal Medicine, 1993 - 1996
University of Bern Faculty of MedicineClass of 1989

Certifications & Licensure

CA State Medical License 2008 - 2026
FL State Medical License 2001 - 2010
NY State Medical License 2000 - 2003
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Super Doctor SuperDoctors.com

Clinical Trials

Phase I Trial of Valproic Acid and Epirubicin in Solid Tumor Malignancies Start of enrollment: 2004 Mar 01
Completed
Phase 1
Panobinostat and Epirubicin in Treating Patients With Metastatic Malignant Solid Tumors Start of enrollment: 2009 Sep 13
Completed
Phase 1
Lisinopril or Coreg CR® in Reducing Side Effects in Women With Breast Cancer Receiving Trastuzumab Start of enrollment: 2010 Mar 01
Completed
Phase 2
Valproic Acid in Combination With FEC100 for Primary Therapy in Patients With Breast Cancer Start of enrollment: 2008 Dec 10
Terminated
Phase 2
Safety of 24-hour Infusion of ON 01910.Na in Combination With Gemcitabine in Advanced Solid Tumors Start of enrollment: 2010 Jan 01
Completed
Phase 1
Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma Start of enrollment: 2010 Jul 20
Completed
Phase 1, Phase 2
An Extension Study of NKTR-102 in Cancer Patients Previously Enrolled in NKTR-102 Studies Start of enrollment: 2011 Oct 01
Completed
Phase 2
Pazopanib in Combination With PCI-24781 in Patients With Metastatic Solid Tumors Start of enrollment: 2012 Jun 25
Active, not recruiting
Phase 1
Eribulin in Combination With Cyclophosphamide in Patients With Solid Tumor Malignancies Start of enrollment: 2012 Mar 27
Completed
Phase 1, Phase 2
A Phase Ib/II Study of BYL719 and Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Start of enrollment: 2012 Nov 12
Terminated
Phase 1, Phase 2
A Dose Escalation Study of OMP-52M51 in Subjects With Solid Tumors Start of enrollment: 2013 Feb 01
Completed
Phase 1
Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer Start of enrollment: 2013 Oct 22
Active, not recruiting
Phase 1, Phase 2
A Study in Cancer Patients to Evaluate the Effect of a Single Dose of NKTR-102 (Etirinotecan Pegol) on the QTc Interval and to Assess Pharmacokinetics and Safety Start of enrollment: 2014 Feb 01
Completed
Phase 1
A Study in Cancer Patients With Hepatic Impairment to Evaluate the Pharmacokinetics and Safety of NKTR-102 (Etirinotecan Pegol) Start of enrollment: 2013 Nov 01
Completed
Phase 1
Study of the Glutaminase Inhibitor CB-839 in Solid Tumors Start of enrollment: 2014 Feb 01
Completed
Phase 1
A Phase 1a/b Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of OMP-131R10 Start of enrollment: 2015 Jul 16
Completed
Phase 1
Phase Ib Study of Alpelisib With Cisplatin in Patients With HPV+ Solid Tumor Malignancies Start of enrollment: 2016 Dec 01
Terminated
Phase 1
64-Cu Labeled Brain PET/MRI for MM-302 in Advanced HER2+ Cancers With Brain Mets Start of enrollment: 2016 Apr 01
Withdrawn
Early Phase 1
Rucaparib and Irinotecan in Cancers With Mutations in DNA Repair Start of enrollment: 2018 Jan 12
Completed
Phase 1
Pembrolizumab and Tamoxifen With or Without Vorinostat for the Treatment of Estrogen Receptor Positive Breast Cancer Start of enrollment: 2021 Mar 11
Terminated
Phase 2
Abexinostat, Palbociclib, and Fulvestrant for the Treatment of Breast or Gynecologic Cancer Start of enrollment: 2021 Mar 31
Withdrawn
Phase 1
Join now to see all

Publications & Presentations

PubMed

Updated Survival Follow-Up for Phase Ib Trial of the Histone Deacetylase Inhibitor Abexinostat With Pazopanib in Patients With Solid Tumor Malignancies.
Erica S Tsang, Rahul R Aggarwal, Emily K Bergsland, Susan Calabrese, Alexandrine Rozie
JCO Precision Oncology. 2024-11-01
1 citations
A Phase II Trial of the WEE1 Inhibitor Adavosertib in SETD2-Altered Advanced Solid Tumor Malignancies (NCI 10170).
Edward Maldonado, W Kimryn Rathmell, Geoffrey I Shapiro, Naoko Takebe, Jordi Rodon
Cancer Research Communications. 2024-07-01
1 citations
Late-onset Proteus syndrome with cerebriform connective tissue nevus and subsequent development of intraductal papilloma.
Emily W Modlin, Anne M Slavotinek, Thomas N Darling, Stanley Lipkowitz, Frederic G Barr
American Journal of Medical Genetics. Part A. 2022-09-01

Lectures

Relacorilant (RELA) with nab-paclitaxel (NP): Safety and activity in patients with pancreatic ductal adenocarcinoma (PDAC) and ovarian cancer (OvCA).
2019 ASCO Annual Meeting - 6/1/2019
A phase 1/2 study of relacorilant + nab-paclitaxel (nab-pac) in patients (pts) with solid tumors: The dose-finding phase.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
Exhausted CD8+ cells (Tex) to predict response to PD-1 therapy in estrogen receptor (+) hormone therapy resistant breast cancer predictive of response to immune checkp...
2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018

Press Mentions

California: Identical Twins Diagnosed with Identical Breast Cancer Just Weeks ApartAugust 6th, 2019
Identical Mirror Twins Diagnosed with Similar Breast Cancer Just Weeks ApartAugust 6th, 2019
Identical Twin Sisters Diagnosed with Identical Breast Cancer Within Weeks of One AnotherAugust 6th, 2019
Join now to see all